Genomics analytics platform developer Sophia Genetics has gone public ten years after it was co-founded by researchers from EMBL, Stanford and University of Geneva

UC Berkeley’s cancer therapy developer priced a $304m initial public offering at the top of its range.

Yale University is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.

Harvard spinout TScan Therapeutics has successfully listed on the Nasdaq Global Market.

The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.

Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.

University of Washington spinout Icosavax has filed for an initial public offering on the Nasdaq Global Select Market, with financial terms yet to be set.

UC Berkeley’s cell therapy developer has filed for an initial public offering.

Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.

CMU-founded language learning platform developer Duolingo was valued at $2.4bn as of its last funding round in November 2020.